Live attenuated Salmonella enterica serovar Choleraesuis vaccine vector displaying regulated delayed attenuation and regulated delayed antigen synthesis to confer protection against Streptococcus suis in mice

Vaccine. 2015 Sep 11;33(38):4858-67. doi: 10.1016/j.vaccine.2015.07.063. Epub 2015 Aug 1.

Abstract

Salmonella enterica serotype Choleraesuis (S. Choleraesuis) and Streptococcus suis (S. suis) are important swine pathogens. Development of a safe and effective attenuated S. Choleraesuis vaccine vector would open a new window to prevent and control pig diseases. To achieve this goal, the mannose and arabinose regulated delayed attenuated systems (RDAS), Δpmi and ΔPcrp::TT araC PBADcrp, were introduced into the wild type S. Choleraesuis strain C78-3. We also introduced ΔrelA::araC PBADlacI TT to achieve regulated delayed antigen synthesis and ΔasdA to constitute a balanced-lethal plasmid system. The safety and immunogenicity of the resulted RDAS S. Choleraesuis strain rSC0011 carrying 6-phosphogluconate dehydrogenase (6-PGD) of S. suis serotype 2 (SS2) were evaluated in vitro and in vivo. Compared with the wild type parent strain C78-3 and vaccine strain C500, a live attenuated S. Choleraesuis vaccine licensed for piglet in China, the results showed that the survival curves of the vaccine strain rSC0011 were similar to those of strains C78-3 and C500 at the early stage of infection, but lower than those of C78-3 and higher than those of C500 at the later stage in both porcine alveolar macrophages and peripheral porcine monocytes. The LD50 of the RDAS strains rSC0011 by oral route in mice was close to that of C500 and 10,000-fold higher than that of C78-3. Similar results were achieved by intraperitoneal (i.p.) route, suggesting that the RDAS strains rSC0011 achieved similar attenuation as C500. However, the RDAS strain rSC0011 was superior to C500 in colonization of Peyer's patches. Adult mice orally immunized with strain rSC0011 carrying a plasmid expression 6-phosphogluconate dehydrogenase (6-PGD) gene from SS2 developed strong immune responses against 6-PGD and Salmonella antigens, and conferred high protection against i.p. challenge with SS2.

Keywords: 6-PGD; Regulated delayed antigen synthesis; Regulated delayed attenuation system; Salmonella Choleraesuis; Streptococcus suis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Antigens, Bacterial / biosynthesis*
  • Antigens, Bacterial / genetics
  • Disease Models, Animal
  • Drug Carriers*
  • Gene Expression Regulation, Bacterial
  • Lethal Dose 50
  • Mice
  • Salmonella enterica / genetics*
  • Salmonella enterica / growth & development
  • Streptococcal Infections / immunology
  • Streptococcal Infections / prevention & control
  • Streptococcal Infections / veterinary*
  • Streptococcal Vaccines / administration & dosage
  • Streptococcal Vaccines / adverse effects
  • Streptococcal Vaccines / genetics
  • Streptococcal Vaccines / immunology*
  • Streptococcus suis / genetics
  • Streptococcus suis / immunology*
  • Survival Analysis
  • Treatment Outcome
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / adverse effects
  • Vaccines, Attenuated / genetics
  • Vaccines, Attenuated / immunology
  • Vaccines, Synthetic / administration & dosage
  • Vaccines, Synthetic / adverse effects
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / immunology

Substances

  • Antigens, Bacterial
  • Drug Carriers
  • Streptococcal Vaccines
  • Vaccines, Attenuated
  • Vaccines, Synthetic